Development of nitroimidazopyrans and nitroimidaoxazoles for tuberculosis chemotherapy

Mohammad Asif
2014 El Mednifico Journal  
The conventional approach to antitubercular drug development requires introduction of novel molecules for the treatment of resistant mycobacterium strains. The nitroimidazopyrans, nitroimidaoxazoles and other analogs are being studied as antitubercular agents and their characteristics form the basis of this review. These new tuberculosis treatments shorten the duration of treatment and/or reduce the number of doses, improve the coverage of MDR-TB/XDR-TB and are more effective in treatment of latent TB infection. (El Med J 2:4; 2014)
doi:10.18035/emj.v2i4.253 fatcat:6fwas4vvyvbrxghiizlw5n6vdm